Jefferies raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $13 from $8 and keeps a Buy rating on the shares ahead of ...

The rising prevalence of allergic diseases such as food allergies, allergic rhinitis, asthma, and atopic dermatitis is a ...

Vernal keratoconjunctivitis (VKC) is an ocular disorder characterized by severe inflammation affecting both the cornea and ...

TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...

In addition, the now expected decline in revenues from $150 million in 2025 to $125 million implies a significant ...

Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

Atopic dermatitis is a chronic inflammatory skin disease characterized by epidermal skin barrier dysfunction and altered immune response, affecting an estimated 7% of adults and up to 20% of children ...

Corvus Pharmaceuticals Inc (CRVS) progresses with promising trials and designations, despite reporting a significant net loss for the quarter.